HOME >> BIOLOGY >> NEWS
Novel test identifies lymphoma patients likely to respond to new therapy

February 20, 2007 (Bronx, NY) Researchers at the Albert Einstein College of Medicine of Yeshiva University have discovered a genetic signature identifying cases of lymphoma that are uniquely susceptible to a newly developed molecular targeted therapy. As a result, physicians organizing clinical trials of the new therapy will be able to enroll patients wholl be most likely to benefit from it.

The research was led by Dr. Ari Melnick, assistant professor of developmental & molecular biology and medicine at Einstein, who also developed the new lymphoma therapy. The study appears in the February 20 issue of the Proceedings of the National Academy of Sciences.

Each year more than 60,000 Americans are diagnosed with B cell lymphomastumors of cells of the immune system that include Hodgkins and non-Hodgkins lymphomas. B cells are the immune-system cells that make antibodies. Genetic aberrations can cause B cells to multiply uncontrollably, causing B cell lymphomas.

Dr. Melnicks study focused on a gene called BCL6. The protein it codes for is a transcriptional repressor, which means that it can shut off the functioning of genes in B cells and other cells of the immune system and prevent them from being expressed. The BCL6 protein is normally produced only during a specific stage of B cell development and is never made again. But deregulation of BCL6 can cause the protein to be produced when it shouldnt be. The unwelcome presence of the BCL6 protein blocks the expression of important genes that normally protect cells from becoming cancerous. As a result, malignant B-cell lymphomas occur.

Mutations or chromosomal rearrangements that deregulate BCL6 are responsible for many cases of diffuse large B cell lymphomaan aggressive cancer that accounts for up to 30 percent of newly diagnosed non-Hodgkins lymphoma cases. In a 2004 Nature Medicine article, Dr. Melnick and colleagues described a peptide, which they dubbed BPI, that showed pr
'"/>

Contact: Karen Gardner
kgardner@aecom.yu.edu
718-430-3101
Albert Einstein College of Medicine
20-Feb-2007


Page: 1 2

Related biology news :

1. Novel sugar-to-hydrogen technology promises transportation fuel independence
2. Novel system developed to turn data into real-time, interactive 3-D images
3. Novel strategies for healthy aging
4. Novel salamander robot crawls its way up the evolutionary ladder
5. Novel laboratory technique nudges genes into activity
6. Novel approaches to tackling obesity, cancer and MRSA
7. Novel approach to cancer drug given major boost
8. Novel regulation of the common tumor suppressor PTEN
9. Novel EGFR ectodomain mutations in glioblastoma
10. Novel regulatory mechanism identified for key tumor suppressor p53
11. Novel experiment documents evolution of genome in near-real time

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/25/2019)... ... September 25, 2019 , ... LeadingBiotech , ... dialogue, today announces its inaugural South CEO conference to be held ... , Co-produced by Tulane University, this invitation-only meeting convenes biopharma executives to discuss ...
(Date:9/24/2019)... (PRWEB) , ... September 24, 2019 , ... ... its technology driven portfolio of 3D porous titanium spinal implants with the expansion ... Ti3D implant offerings while more than tripling the number of cervical and lumbar ...
(Date:9/22/2019)... ... September 20, 2019 , ... ... are adjusting to client demands for precision medicine products. The report, Lab ... $19 billion in 2018, the pharma/bio sector is the largest source of demand ...
Breaking Biology News(10 mins):
(Date:10/3/2019)... ... 02, 2019 , ... Rapid Novor, Inc., the world's leader ... has moved into a new, 5000 sqft, purpose-built, state-of-the-art facility. Now home to ... company's continuous commitment to quality research and service offerings. , The ...
(Date:9/24/2019)... ... September 24, 2019 , ... ... delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies, and ... company focused on the development of therapies to treat central nervous system ...
(Date:9/17/2019)... ... September 17, 2019 , ... Catalent, a ... and Clinical Supplies Management, Asia Pacific (APAC) will present at the upcoming 3rd ... Sept. 25-26, 2019. , On Thursday, Sept. 26, at 10:10 a.m., Ms. Delaney ...
(Date:9/17/2019)... , ... September 16, 2019 , ... ... via CNBC on Saturday, September 21st @11:00am ET. Check local listings for more ... Ltd. (Credo Biomedical), a molecular diagnostic company from Singapore dedicated to developing ...
Breaking Biology Technology:
Cached News: